
Table of Contents

Section I: General Information

Chapter 1	EMA and Other Regulatory Bodies	1
	<i>Updated by Ratinder Dhami, MSRA, RAC</i>	
Chapter 2	History of Regulations	13
	<i>Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS</i>	
Chapter 3	Overview of Drug and Biologic Regulatory Pathways	31
	<i>Updated by Kathrin Schalper, PhD, RAC</i>	
Chapter 4	Preparing for EMA Meetings Prior to Submission of a Marketing Authorisation Application	41
	<i>Updated by Kell Cannon, Kate Dion and Cindy DiBiasi</i>	
Chapter 5	Preparing for EMA Meetings During Review of a Marketing Authorisation Application	53
	<i>By Kell Cannon, Kate Dion and Cindy DiBiasi</i>	
Chapter 6	Pricing and Reimbursement	61
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 7	Health Technology Assessment (HTA)	77
	<i>Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC</i>	
Chapter 8	The Paediatric Regulation	93
	<i>Updated by Karl-Heinz Huemer, PhD, MD</i>	
Chapter 9	Advertising and Promotion	103
	<i>Updated by Karen Zhou, JD, MS, RAC</i>	
Chapter 10	Enforcement and Competent Authorities	115
	<i>Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS</i>	
Chapter 11	Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery	121
	<i>Updated by Yolanda García Barruso</i>	
Chapter 12	Regulatory Strategy	135
	<i>Updated by Karen Fan, MSc, PEng, RAC</i>	

Section II: Medical Devices

Chapter 13	The New Medical Devices Regulation and In Vitro Diagnostic Medical Devices Regulation	141
	<i>Updated by Gert Bos, MSc, PhD, FRAPS and Erik Vollebregt, LL.M</i>	
Chapter 14	The European Medical Devices Legal System	151
	<i>Updated by Gert Bos, MSc, PhD, FRAPS and Erik Vollebregt, LL.M</i>	

Chapter 15	Medical Devices: Legislation and Classification	183
	<i>Updated by Ruthanne Vendy, RAC and Chauneen Leah Wood, MS, RAC</i>	
Chapter 16	In Vitro Diagnostic Medical Devices.....	207
	<i>Updated by Erik Vollebregt, LLM</i>	
Chapter 17	General Safety and Performance Requirements and Technical Documentation (EU MDR, EU IVDR)	221
	<i>Updated by Darin Oppenheimer, DRSc, RAC, Suraj Ramachandran, MS, RAC and George Cusatis, MS, RAC</i>	
Chapter 18	Medical Device Preclinical Testing	229
	<i>Updated by Jan-Paul van Loon, MSc, PhD and Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 19	Clinical Evaluation and Clinical Investigations	237
	<i>Updated by Loes Pelgrim, MSc and Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 20	Medical Device Conformity Assessment Procedure	243
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 21	Medical Device Compliance: Postmarket Requirements	257
	<i>Updated by Tran Do and Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 22	Medical Device National Particularities.....	271
	<i>Updated by Robert Falcone, PhD</i>	
 Section III: Medicinal Products		
Chapter 23	Overview of Authorisation Procedures for Medicinal Products.....	277
	<i>Updated by Sharry Arora, MPharm</i>	
Chapter 24	Adaptive and Alternative Pathways	295
	<i>Updated by Kathrin Schalper, PhD, RAC</i>	
Chapter 25	Preclinical Testing and Good Laboratory Practice Regulations	301
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 26	Medicinal Product Clinical Trials	309
	<i>Updated by Ashley Clark, MSc, RAC</i>	
Chapter 27	Registration Procedures for Medicinal Products.....	341
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 28	Quality Systems and Inspectorate Process—Pharmaceuticals	363
	<i>Updated by Treena Jackson, MS, MA, CQA, CSSGB, RAC and Siegfried Schmitt, PhD</i>	
Chapter 29	Generic Medicinal Products	377
	<i>Updated by Nicole Beard MSc, PhD</i>	
Chapter 30	Biosimilar Medicinal Products.....	393
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 31	Nonprescription Medicinal Products	403
	<i>Updated by Nicole Beard MSc, PhD</i>	

Chapter 32	Marketing Authorisations for Products Derived From Biotechnology	413
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 33	Pharmaceutical Postauthorisation Requirements and Compliance With the Marketing Authorisation	423
	<i>Updated by Sharry Arora, MPharm</i>	
Chapter 34	Pharmacovigilance	437
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 35	Regulatory Framework for Advanced Therapy Medicinal Products	451
	<i>By Daniela Drago, PhD, RAC, Florence Houn, MD, MPH and James McBlane, PhD</i>	
Chapter 36	Human Tissue Regulation	471
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 37	Vaccines.....	489
	<i>Updated by Frédéric Béard</i>	

Section IV: Foods

Chapter 38	Food Supplements	501
	<i>Updated by Manfred Ruthsatz, PhD, RAC, FRAPS</i>	
Chapter 39	Food for Special Medical Purposes.....	511
	<i>Updated by Manfred Ruthsatz, PhD, RAC, FRAPS</i>	

Section V: Other Product Classifications

Chapter 40	Products Manufactured From Human Blood or Plasma.....	519
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 41	Orphan Medicinal Products.....	529
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 42	Combination Products.....	543
	<i>Updated by Claudia Ising, FRAPS, RAC</i>	

Section VI: Resources

Chapter 43	Regulatory Information Resources.....	553
	<i>Updated by Meredith Brown-Tuttle, FRAPS and Gert Bos, MSc, PhD, FRAPS</i>	

Appendices

Comparative Matrix of EU Legislation Across Product Lines.....	575
Glossary	623
Index	643

Figures

Figure 1-1.	EMA Mission.....	3
Figure 1-2.	EMA Organisational Structure	9
Figure 5-1.	Approximate Representation of Key CHMP, CAT and PRAC Feedback and Meetings Based on Standard Assessment Review Timeline	55
Figure 5-2.	Example Timeline for CHMP Meeting Preparation	57

Figure 6-1.	Factors Influencing Medicinal Product Pricing	62
Figure 6-2.	Overview of ERP across Europe (2013)	64
Figure 6-3.	Summary of Economic Evaluation Methods.....	66
Figure 6-4.	Types of Cost Containment Policies Adopted by Member States.....	67
Figure 6-5.	German Pricing for Medicinal Products Under AMNOG	70
Figure 7-1.	Process Map for France	85
Figure 7-2.	Process Map for Germany	86
Figure 7-3.	Mean Length of Time From EMA Authorisation to HTA Decision for Oncology Products.....	88
Figure 8-1.	PIP Procedure.....	98
Figure 11-1.	Comparison of EU <i>FMD</i> and Other Countries' Falsified Medicines Legislation	123
Figure 11-2.	Routes in the Medicinal Product Supply Chain by Which Falsified Active Substances may Reach Patients	125
Figure 11-3.	An Example of the Common Logo Online Retailers of Medicines Must Display	128
Figure 11-4.	Flowchart Representing Product and Information Flow With Unique Product Identifiers and Accompanying Verification and Repository Systems.....	131
Figure 13-1.	Supply Chain Controls	143
Figure 13-2.	Proposed <i>EU IVDR</i> Classification Rules.....	145
Figure 13-3.	Governance Structure for the <i>EU MDR</i> and <i>EU IVDR</i>	147
Figure 14-1.	Simplified EU Legislative Process	153
Figure 14-2.	Flow Chart for the Conformity Assessment Procedures in Directive 93/42/EEC on Medical Devices	156
Figure 14-3.	Flow Chart for the Conformity Assessment Procedures Provided for in Directive 90/385/EEC on Active Implantable Medical Devices	157
Figure 14-4.	Flow Chart for the Conformity Assessment Procedures Provided for in Directive 98/79/EEC on in Vitro Diagnostic Medical Devices.....	158
Figure 14-5.	Clinical Evaluation Cycle	159
Figure 14-6.	<i>EU MDR</i> and <i>EU IVDR</i> Governance Structure	176
Figure 20-1.	Class III Device Conformity Assessment Procedure Options.....	248
Figure 20-2.	Class IIb Conformity Assessment Procedures.....	249
Figure 20-3.	Class IIa Conformity Assessment Procedure.....	249
Figure 20-4.	Class I Device, Self-Declaration or Self-Certification.....	250
Figure 20-5.	<i>AIMDD</i> Conformity Assessment Procedure	250
Figure 20-6.	IVD Conformity Assessment Procedure	251
Figure 20-7.	Self-Testing IVD Conformity Assessment Procedure	251
Figure 20-8.	<i>IVDD</i> Annex II List B Conformity Assessment Procedures	252
Figure 20-9.	High-Risk IVD Conformity Assessment Procedure	253
Figure 24-1.	Product Eligibility for Adaptive Pathways Approach (Source: EMA, 2016).....	297
Figure 26-1.	Clinical Trial Legislative Improvements.....	312
Figure 26-2.	Regulation (EU) 536/2014.....	313
Figure 26-3.	Clinical Trial Authorization Procedure.....	326
Figure 26-4.	Clinical Trial Application Scientific Assessment	327
Figure 26-5.	Clinical Trial Application: Part II Assessment	328
Figure 26-6.	Serious Adverse Event Reporting.....	332
Figure 27-1.	Initial Marketing Authorisation Application Through the Centralised Procedure	355
Figure 27-2.	Initial Marketing Authorisation Application Through the Decentralised Procedure.....	356
Figure 27-3.	Initial Marketing Authorisation Application Through National Procedure and Mutual Recognition Procedure	357
Figure 28-1.	Drug Lifecycle Regulations	364
Figure 28-2.	Assessors and Inspectors.....	365
Figure 28-3.	EU Legal Instruments.....	366
Figure 28-4.	Inspections as Part of the Drug Approval Process	367
Figure 30-1.	Biosimilar Development.....	395
Figure 30-2.	Stages of Development of a Biosimilar Medicine.....	396
Figure 30-3.	Timeline for Development of a Biosimilar Medicine.....	397

Figure 30-4.	Biosimilar Product Development and Marketing Approval	399
Figure 34-1.	Pharmacovigilance System Master File	441
Figure 34-2.	ICSR Expedited Submissions Requirements	445
Figure 34-3.	Signal Management Lifecycle	447
Figure 35-1.	Decision Tree for Potential Pathways and Expedited Evaluation Programs in the EU	454
Figure 35-2.	Decision Tree for Classification of TEPs and CTMPs.....	458
Figure 35-3.	Decision Tree for the Classification of GTMPs	459
Figure 37-1.	General Principles of VAMF Certification.....	491
Figure 37-2.	Procedure for Seasonal Influenza Vaccines in the EU (EMA/56793/2014).....	495
Figure 41-1.	Simplified View of the Designation Criteria	532
Figure 41-2.	EMA Orphan Drug Designation Guide.....	534

Tables

Table 3-1.	Differences Between Conditional Marketing Authorisation and Marketing Authorisation Under Exceptional Circumstances.....	36
Table 4-1.	Overview of the Key EMA Advice Meetings and Their Goals	43
Table 4-2.	Overview of the Different Steps Required for Each Meeting	45
Table 4-3.	Timeline for Key Meeting Steps	46
Table 5-1.	EMA Scientific Committees: Roles.....	54
Table 6-1.	Overview of Reference Pricing and Country Baskets in Europe	65
Table 7-1.	HTA and Associated Organisations in Select EU Member States.....	82
Table 7-2.	Comparison of HTA in Germany, France, UK, Italy and Spain	83
Table 7-3.	Summary of Time From EMA Authorisation to HTA Decision and Outcome.....	87
Table 11-1.	Definitions of Key Terms in This Chapter	124
Table 11-2.	Worldwide Examples of SFFC Medicines From 2008 to Present.....	126
Table 11-3.	Different Medicinal Product Supply Chain Stakeholder Requirements Under the <i>FMD</i>	127
Table 11-4.	<i>FMD</i> Definitions of Active Substances and Excipients	128
Table 11-5.	EU Initiatives Relevant to the <i>FMD</i>	129
Table 11-6.	Status of Third Country Listing Requests	130
Table 12-1.	Regulatory Key Questions During Development.....	137
Table 14-1.	New Approach Areas.....	154
Table 14-2.	EU Member States and Affiliated Countries Competent Authorities.....	161
Table 14-3.	European Commission Working Groups and Their Activities	166
Table 14-4.	European Industrial Trade Associations	167
Table 14-5.	Comparison of MDD and EU MDR Definition of a Medical Device	168
Table 14-6.	MEDDEV Guidance Documents.....	172
Table 14-7.	European Commission Consensus Statements.....	174
Table 14-8.	Informative Documents Issued by the European Commission.....	174
Table 14-9.	NBOG Documents (NBOG Best Practice Guides).....	175
Table 15-1.	<i>MDR</i> Annex VIII, Chapter III Classification Matrix	188
Table 15-2.	<i>MDR</i> Classification Rules for Non-Invasive Medical Devices	189
Table 15-3.	<i>MDR</i> Classification Rules for Invasive Medical Devices.....	190
Table 15-4.	<i>MDR</i> Classification Rules for Active Medical Devices	191
Table 15-5a.	Special <i>MDR</i> Rules: Medical Devices	192
Table 15-5b.	Special <i>MDR</i> Rules: Medical Devices	192
Table 15-6.	Comparison of <i>MDD</i> and <i>MDR</i> Device Classification Rules.....	194
Table 15-7.	<i>IVDR</i> Annex VIII, I Classification Matrix	202
Table 15-8.	Comparison of <i>IVDD</i> and <i>IVDR</i> Device Classification Rules.....	204
Table 16-1.	Examples of General Laboratory Use Products and IVD Medical Devices	210
Table 17-1.	General Safety and Performance Requirements Checklist (Annex I of <i>EU MDR</i> and <i>EU IVDR</i>)..	223
Table 18-1.	Basic Design Traceability Matrix (DTM) for Connecting Requirements to Test Results.....	231
Table 20-1.	Conformity Assessment Procedures	246
Table 20-2.	<i>AIMDD</i> Conformity Assessment Documentation	246
Table 20-3.	<i>MDD</i> Conformity Assessment Documentation.....	247

Table 20-4.	<i>IVDD</i> Conformity Assessment Documentation.....	247
Table 20-5.	Internal Production Control	254
Table 20-6.	EC Type-Examination	254
Table 20-7.	Production Quality Assurance	254
Table 20-8.	Product Quality Assurance	254
Table 20-9.	Product Verification	254
Table 20-10.	Full Quality Assurance System.....	254
Table 20-11.	Authorised Representatives.....	255
Table 21-1.	Provisions for Providing Feedback about Medical Devices.....	259
Table 21-2.	Eudamed Data Repository	262
Table 21-3.	Comparison of Safeguard Clause and Health Monitoring Measures	267
Table 22-1.	EU Outermost Regions.....	272
Table 22-2.	Current Directives and New Regulations for Medical Devices, AIMDs and IVDs	272
Table 22-3.	Translation Requirements for Medical Devices, AIMDs and IVDs.....	273
Table 22-4.	National Languages of the EU, Iceland, Liechtenstein and Norway	274
Table 23-1.	Standard Timetable for Evaluation of a Centralised Application	284
Table 23-2.	Mutual Recognition Procedure Flowchart.....	287
Table 23-3.	Decentralised Procedure Flowchart	290
Table 26-1.	Summary of Selected Significant Changes Under Regulation (EU) No. 536/2014 (<i>ECTR</i>)	314
Table 26-2.	Definitions of Selected <i>Clinical Trials Directive</i> and <i>ECTR</i> Terms.....	316
Table 26-3.	General Contents of Applications to Ethics Committees and National Competent Authorities	321
Table 26-4.	Contents of Clinical Trial Application Dossier per the <i>ECTR</i>	329
Table 26-5.	Contents of DSUR.....	334
Table 27-1.	EU Module 1 Contents	351
Table 27-2.	EU eCTD Envelope Information.....	352
Table 29-1.	Legal Basis of EU Applications from Directive 2001/83/EC.....	381
Table 30-1.	Data Package Required for a Marketing Authorisation Application to EMA	400
Table 31-1.	Some Common Health Conditions Treated Using Nonprescription Medication	405
Table 31-2.	Comparison of EU MAA Procedure Advantages and Risks for Nonprescription Medicines	406
Table 34-1.	Overview of Good Pharmacovigilance Practices	439
Table 34-2.	Periodic Benefit-Risk Evaluation Report (PBRER), Development Safety Update Report (DSUR) and Risk Management Plan (RMP) Interchangeable Modules	444
Table 35-1.	EU Pathways and Expedited Evaluation Programs That Might Apply to ATMPs.....	453
Table 35-2.	ATMPs That Have Been Granted a Marketing Authorisation in the EU	455
Table 35-3.	Recent Examples of CAT ATMP Classifications.....	457
Table 36-1.	Serological Donor Testing Requirements	475
Table 36-2.	Structure of the Single European Code.....	476
Table 36-3.	Qualifications and Responsibilities of the Responsible Person Under the EUTCD, Qualified Person for Human Medicinal Products and Responsible Person for Regulatory Compliance Under the <i>EU MDR</i>	479
Table 36-4.	Standard Timetable for Initial ATMP Marketing Authorisation Application Evaluation Under the Centralised Procedure.....	481
Table 36-5.	General Applicable Regulatory Framework for Medical Products Containing Human Tissue Intended for Human Clinical use and its Interconnection with Directive 2004/23/EC (<i>Tissues and Cells Directive</i>)	484
Table 40-1.	Medicinal Products Derived From Human Plasma and Their Indications	521
Table 43-1.	EMA's Committees and Working Parties.....	558
Table 43-2.	National Competent Authorities	562
Table 43-3.	Eligible Industry Stakeholder Organisations.....	565
Table 43-4.	EDQM Databases	567